Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.60 |
| ▸ | MEN1 | O00255 | 7/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | THRA | P10827 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.51 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30914344 | 0.81 | MAPT (0.63) | MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL929507 | 0.81 | MAPT (0.63) | MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL10943066 | 0.79 | KMT2A (0.94) | KMT2AMEN1MAPTPOLBBLM | |
| SCHEMBL14134378 | 0.79 | NPC1 (0.64) | KMT2AMEN1MAPTPOLBBLM | |
| SCHEMBL10944138 | 0.79 | ALOX5 (0.82) | KMT2AMEN1MAPTPOLBBLM | |
| SCHEMBL3336352 | 0.78 | KDM4E (0.65) | KMT2AMEN1MAPTPOLBBLM | |
| SCHEMBL4831943 | 0.77 | MEN1 (0.69) | KMT2AMEN1MAPTPOLBBLM | |
| SCHEMBL18300094 | 0.77 | MEN1 (1.00) | KMT2AMEN1MAPTPOLBBLM | |
| SCHEMBL32690121 | 0.77 | MEN1 (1.00) | KMT2AMEN1MAPTPOLBBLM | |
| SCHEMBL3334674 | 0.76 | ALOX5 (0.53) | KMT2AMEN1MAPTPOLBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302565-A1 | KINASE INHIBITORS FOR PREVENTING OR TREATING PATHOGEN INFECTION AND METHOD OF USE THEREOF | M.D. ANDERSON CANCER CENTER (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302565-A1 | KINASE INHIBITORS FOR PREVENTING OR TREATING PATHOGEN INFECTION AND METHOD OF USE THEREOF | M.D. ANDERSON CANCER CENTER (US) | 2012-11-29 | — | — | US | disclosed |
| US-8268809-B2 | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof | EMORY UNIVERSITY (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268809-B2 | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof | EMORY UNIVERSITY (US) | 2012-09-18 | — | — | US | disclosed |
| EP-2471529-A2 | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof | Emory University (US) | 2012-07-04 | — | — | EP | disclosed |
| EP-2364702-A2 | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof | Emory University (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20100249122-A1 | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof | EMORY UNIVERSITY (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249122-A1 | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof | EMORY UNIVERSITY (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100144738-A1 | INHIBITORS OF C-MET AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2010-06-10 | — | — | US | disclosed |
| US-20100144738-A1 | INHIBITORS OF C-MET AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2010-06-10 | — | — | US | disclosed |
| US-20100144738-A1 | INHIBITORS OF C-MET AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2010-06-10 | — | — | US | disclosed |
| WO-2008079460-A2 | TYROSINE KINASE INHIBITORS FOR PREVENTION OR TREATMENT OF INFECTION | EMORY UNIVERSITY (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008030744-A2 | INHIBITORS OF C-MET AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008030744-A2 | INHIBITORS OF C-MET AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249122-A1 | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof | MAP3K1, MAP3K2, MAP3K6 | KMT2A 1524/4885MEN1 4195/4885MAPT 3703/4885 |
| US-20100144738-A1 | INHIBITORS OF C-MET AND USES THEREOF | MET, HGF, HGFAC | KMT2A 1909/4885MEN1 82/4885MAPT 3176/4885 |
| US-20120302565-A1 | KINASE INHIBITORS FOR PREVENTING OR TREATING PATHOGEN INFECTION AND METHOD OF USE THEREOF | MAP3K1, MAP3K2, MAP3K6 | KMT2A 1524/4885MEN1 4195/4885MAPT 3703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.